Beruflich Dokumente
Kultur Dokumente
:
, ;
. MD,
Phds, FESC, FEAS
.
25%
Deaths<65y by in men
18%
Deaths<65y by in women
36%
Deaths by cause in men
43%
Deaths by cause in women
Mechanism
Cholesterol biosynthesis,
LDL-R-Expression
Fibrates
Catabolism of Lipoproteins
rich of TG
Resins
Interruption of the
interohepatic circuit of the bile
acids
Nicotinic acid
Ezetimibe
3 FA
VLDL-Synthesis
absorption
VLDL-Synthesis
Effects
LDL
VLDL
VLDL
, LDL
LDL
VLDL
LDL
VLDL
LDL
1987), with apoB (125 mg/dl) & family history of CAD. All
subjects had evidence of coronary atherosclerosis on their baseline
angiograms with at least one 50% stenosis/ 3 lesions of 30%
stenosis
HATS (simvastatin+niacin): 160 <63 ys &<70 with clinical CAD
angiographically confirmed (at least one 50% stenosis/3 lesions
30% stenosis), with HDL-C35 mg/dl in & 40 mg/dl in
(Jan.1995-Jan. 1997)
AFREGS (gemfibrozil+niacin+cholestyramine): recruited 143 military
retirees <76 yrs with angiographically measurable stenosis 30%- 80%
& HDL-C <40 mg/dl in 1993
Am J Cardiol. 2009 December
Colesevelam + Ezetimibe
TOTAL-C
LDL-C
TG
HDL-C
20
10
5
0
-3
-10
(2)
-14
-20
(2,3)
-20
(2)
-21
(2,4)
-30
-32
-40
10
1. LDLC-C, HDL-C and Total-C values are expressed as mean, whereas TG values are expressed as median.
2. p < 0.0001 vs. Baseline; 3. p < 0.05 vs. Ezetimibe + placebo; 4. p < 0.0001 vs. Ezetimibe + placebo
Colesevelam + Atorvastatin
Atherosclerosis 2001;158:407-416
LDL-C (%)
Placebo
3%
Colesevelam (3.8g/d)
-12%
Atorvastatin (10mg/d)
-38%
Colesevelam
+
Atorvastatin (10 mg/d)
-48%
Atorvastatin (80mg/d)
-53%
FH +
Colesevelam (3.8g/d) vs placebo
LDL-C:
HDL-C:
Apo:
-18.5%
6w
-12.0%
12 w
+3.3%
12 w
-12.2%
12 w
Clin Ther 2010
Colesevelam (3.8g/d)
hs CRP 16%
Am J Cardiol 2006;98: 641-643
(SEAS Study)
Simvastatin
(1054)
Placebo
(4191)
Not re-randomised
(168)
Randomised
(886)
Placebo
(4620)
Simv/Eze
(4650)
Median follow-up 4.9 years
Lost to mortality follow-up 1.5%
25
20
Placebo
15
Simv/Eze
10
0
0
Years of follow-up
The Lancet,, June 2011
Simv/Eze
(n=4650)
Placebo
(n=4620)
213
131
284
162
45
(3.5%) 182
(1.0%) 37
(3.9%)
(0.8%)
207
(4.5%) 218
(4.7%)
(4.6%) 230
(2.8%) 174
(6.1%) 352
(5.0%)
(3.8%)
(7.6%)
16.6% SE 5.4
reduction
(p=0.0021)
5.5% SE 9.4
reduction
(p=0.56)
15.4% SE 4.7
reduction
(p=0.0012)
0.6
0.8
1.0
Simv/Eze better
1.2
1.4
Placebo better
NEJM 2010
NEJM 2010
NEJM 2010
FIELD Study
Lancet 2005;366:1849-61
Rate (%) of 30-day Major Adverse Coronary Events (MACE) among the study
patients according to the age, gender, level of HDL cholesterol, triglycerides, smoking
status, presence of diabetes and hypertension
Tenenbaum, et al. APLoS One